SCHEMBL3892682

SCHEMBL3892682

CCN(CC)c1ccc(N2C(=O)/C(=C/c3ccc(C)o3)SC2=S)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 12/20 0.64
▸ MEN1 O00255 12/20 0.64
▸ KMT2A Q03164 12/20 0.64
▸ ALDH1A1 P00352 8/20 0.64
▸ KDM4E B2RXH2 6/20 0.60
▸ TDP1 Q9NUW8 5/20 0.60
▸ RECQL P46063 4/20 0.60
▸ MAPK1 P28482 4/20 0.60
▸ CYP1A2 P05177 2/20 0.59
▸ SMN1; SMN2 Q16637 2/20 0.59
▸ CYP3A4 P08684 1/20 0.59
▸ CYP2C19 P33261 1/20 0.59
▸ ALOX12 P18054 3/20 0.52
▸ LMNA P02545 2/20 0.52
▸ MCL1 Q07820 2/20 0.52
▸ POLB P06746 8/20 0.51
▸ RAB9A P51151 3/20 0.51
▸ HPGD P15428 1/20 0.51
▸ L3MBTL1 Q9Y468 4/20 0.47
▸ NPSR1 Q6W5P4 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3892687 1.00 MAPT (0.64) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL3897777 0.83 MEN1 (0.65) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL3897769 0.83 MEN1 (0.65) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL3897872 0.83 MAPT (0.65) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL3897874 0.83 MAPT (0.65) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL3904138 0.83 MAPT (0.64) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL3904141 0.83 MAPT (0.64) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL3892130 0.83 MAPT (0.72) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL3892131 0.83 MAPT (0.72) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL23692458 0.80 PTPN12 (0.71) MAPTMEN1KMT2AALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137644-A1 RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS RIGEL PHARMACEUTICALS, INC. (US) 2009-05-28 — — US claimed
WO-2005041951-A2 RHODANINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS RIGEL PHARMACEUTICALS, INC. (US) 2005-05-12 — — WO claimed
US-7566732-B2 Rhodanine compositions for use as antiviral agents RIGEL PHARMACEUTICALS, INC. (US) 2009-07-28 — — US disclosed
US-7566732-B2 Rhodanine compositions for use as antiviral agents RIGEL PHARMACEUTICALS, INC. (US) 2009-07-28 — — US disclosed
US-7566732-B2 Rhodanine compositions for use as antiviral agents RIGEL PHARMACEUTICALS, INC. (US) 2009-07-28 — — US disclosed
US-20090137644-A1 RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS RIGEL PHARMACEUTICALS, INC. (US) 2009-05-28 — — US disclosed
US-20090137644-A1 RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS RIGEL PHARMACEUTICALS, INC. (US) 2009-05-28 — — US disclosed
US-20090137644-A1 RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS RIGEL PHARMACEUTICALS, INC. (US) 2009-05-28 — — US disclosed
US-20060276520-A1 Rhodanine derivatives and pharmaceutical compositions containing them RIGEL PHARMACEUTICALS, INC. (US) 2006-12-07 — — US disclosed
WO-2004043955-A1 RHODANINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM RIGEL PHARMACEUTICALS, INC. (US) 2004-05-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276520-A1 Rhodanine derivatives and pharmaceutical compositions containing them UBQLN1, UBQLN2, UBE2G2 MAPT 1187/4885MEN1 1562/4885KMT2A 901/4885
US-20090137644-A1 RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS RBX1, ITCH, UBQLN1 MAPT 880/4885MEN1 2869/4885KMT2A 1020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback